SLCO1B1 and myopathy: These SLCO1B1-informed statin therapy switches would avert 109 (95% CI 94 to 141) and 3 (95% CI 2 to 5) SLCO1B1-induced myalgias and myopathies, respectively (Figure 2, Supplementary Table S6).